Polyrizon Returns to Nasdaq Compliance After Meeting Listing Requirements

Polyrizon has regained compliance with Nasdaq listing requirements, having met the minimum bid price requirement and satisfied the conditions set by the Nasdaq Hearings Panel. The company will continue to trade on the Nasdaq Capital Market under the ticker symbol "PLRZ." This confirms that Polyrizon has demonstrated compliance with all applicable listing requirements and will maintain its Nasdaq listing.

Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotechnology company focused on intranasal product development, has successfully regained compliance with all Nasdaq listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel's Hearings Advisor on August 13, 2025, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The confirmation satisfies all previously outlined conditions by the Nasdaq Hearings Panel in their July 9, 2025 decision. As a result, Polyrizon will maintain its listing and continue trading on the Nasdaq Capital Market under the ticker symbol "PLRZ" [1].

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays. The company's proprietary Capture and Contain™ (C&C) hydrogel technology functions as a "biological mask" with a thin shield containment barrier in the nasal cavity, providing a barrier against viruses and allergens [2].

This news is significant for investors as it confirms that Polyrizon has met the necessary conditions to maintain its Nasdaq listing. The company's continued compliance with Nasdaq listing requirements ensures its ability to trade on the Nasdaq Capital Market, which is a key platform for publicly traded companies.

Polyrizon has been actively working on its intranasal product development and has recently announced partnerships and appointments to enhance its clinical trial readiness. For instance, the company has partnered with Eurofins CDMO for the manufacturing of clinical trial material for its PL-14 allergy blocker, which is set to enter clinical trials in 2025 [3].

Polyrizon's ability to maintain its Nasdaq listing is a positive sign for the company's long-term prospects and may attract further investment from financial professionals and investors. The company's focus on innovative intranasal products and its commitment to regulatory compliance are key factors that contribute to its market presence.

References:
[1] https://www.stocktitan.net/news/PLRZ/polyrizon-regains-compliance-with-nasdaq-listing-sbpb7qr43s9o.html
[2] https://www.barchart.com/stocks/quotes/PLRZ
[3] https://www.barchart.com/stocks/quotes/PLRZ